Date | Insider | Price | Amount |
---|---|---|---|
11-29-2022 Insider Buy |
Jaime Vieser Director |
$0.65 CAGR » |
$812,500.00 1,250,000 shares |
11-29-2022 Insider Buy |
Robert W. Postma Director |
$0.65 CAGR » |
$487,500.00 750,000 shares |
Also See: Institutional Holders of TCRT
Also See: SEC filings
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 11/30/2022 | |
End date: | 05/10/2024 | |
Start price/share: | $9.60 | |
End price/share: | $1.24 | |
Dividends collected/share: | $0.00 | |
Total return: | -87.08% | |
Average Annual Total Return: | -75.83% | |
Starting investment: | $10,000.00 | |
Ending investment: | $1,291.94 | |
Years: | 1.44 |
Alaunos Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Alaunos Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding TCRT
Free TCRT Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |